ClinicalTrials.gg
CompletedNCT06932211Updated Sep 17, 2026

A Study to Measure the Effect of a Toothpaste Containing Proteins and Enzymes and a Fluoride Toothpaste on Gingival Health

An interventional study of Toothpaste containing proteins and enzymes and Control fluoride toothpaste in Gingival Inflammation and Dental Plaque, sponsored by Unilever R&D. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Unilever R&D (part of Unilever) · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 6 years 5 months after the study started (first participant enrolled Oct 2018, registered Apr 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study is a double-blind, randomised, parallel group efficacy study. A minimum of 240 healthy female and male participants aged 18-70 years will be enrolled onto the study according to the inclusion/exclusion criteria. The accepted participants will then be randomly allocated to one of the two test products which they will use at home, twice a day for the duration of the study. Dental assessments of gingival condition and plaque level will be conducted after 4, 13 and 26 weeks of product use at the study site.

02

Conditions studied

  • Gingival Inflammation
  • Dental Plaque
03

In context

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

This study's enrollment of 251 is above the median of 66 across 507 interventional studies indexed under Gingivitis.

Browse Gingivitis studies →

Lead sponsor

Unilever R&D is the lead sponsor of 71 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be in good general health.
  • Be willing and physically able to carry out all study procedures.
  • Be willing and competent (verbally and cognitively) to give written and complete a medical history form.
  • Have at least 20 natural teeth without subgingival calculus including 5 teeth (excluding 3rd molars) in each quadrant, which can be assessed.
  • Have mean Gingival Index (GI) score between 1.0 and 2.0 (1.0 ≤ Mean GI ≤ 2.0) and mean Plaque Index (PI) ≥ 1.5 at screening and baseline.
  • Not have had a scale and prophylaxis in the month prior to enrolment or have one scheduled prior to the end of the study.
  • Be willing to use only the test products for 6 months, after brushing with the products on site.
  • Brush teeth twice daily (once in the morning and once at night).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding mothers.
  • Subjects who participated in gum health study within 3 months prior to screening.
  • Current participation in any other cosmetic trials, any dental clinical trials or clinical trials.
  • Subjects who have used gum health products in the 4 weeks prior to screening.
  • Obvious signs of untreated caries or significant periodontal disease, which in the opinion of the study dentist, will affect either the scientific validity of the study or if the participant was to participate in the study would affect their wellbeing.
  • Full or partial dentures wearers.
  • Current orthodontic treatment.
  • Smokers or those who have a recent smoking history, including e-cigarettes.
  • Diabetics.
  • Medical condition and/or regular use of any medication which might affect the outcome of the study, as determined by the study dentist, principally a course of anti-inflammatory, antimicrobial or statin drugs within 4 weeks of screening.
  • Taking dietary supplements (e.g. multivitamins, antioxidants, fish oils, etc.).
  • Vegetarians and Vegans.
  • Allergic to any ingredient of study products.
  • The subject is a Unilever employee or a member of the study team.
  • Any participant who, in the judgement of the investigator, should not participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    Test toothpaste

    Toothpaste containing proteins, enzymes and 1450 ppm fluoride as sodium fluoride

    Other: Toothpaste containing proteins and enzymes

  • Active comparator
    Negative control toothpaste

    Toothpaste containing 1450 ppm fluoride as sodium fluoride

    Other: Control fluoride toothpaste

Interventions

  • OtherToothpaste containing proteins and enzymes

    Toothpaste containing proteins, enzymes and 1450 ppm fluoride as sodium fluoride

  • OtherControl fluoride toothpaste

    Toothpaste containing sodium fluoride at 1450 ppm F

06

What researchers measure

Primary outcomes

  1. Change in gingival condition as measured by Gingival Index

    The gingival condition was assessed using gingival index (GI) \[1\]. The scoring criteria were: 0 = Absence of inflammation; 1 = Mild inflammation - slight change in colour and little change in texture; 2 = Moderate inflammation - moderate glazing, redness, oedema, and hypertrophy (bleeding on pressure); 3 = Severe inflammation - marked redness and hypertrophy (tendency to spontaneous bleeding). Each eligible tooth was scored at six sites: facial (body, mesial, distal) and lingual (body, mesial, distal). The participant's score at each timepoint is the average of all tooth sites measured.

    Time frame: 13 weeks

Secondary outcomes

  1. Change in gingival condition as measured by Gingival Index

    The gingival condition was assessed using gingival index (GI) \[1\]. The scoring criteria were: 0 = Absence of inflammation; 1 = Mild inflammation - slight change in colour and little change in texture; 2 = Moderate inflammation - moderate glazing, redness, oedema, and hypertrophy (bleeding on pressure); 3 = Severe inflammation - marked redness and hypertrophy (tendency to spontaneous bleeding). Each eligible tooth was scored at six sites: facial (body, mesial, distal) and lingual (body, mesial, distal). The participant's score at each timepoint is the average of all tooth sites measured.

    Time frame: 4 weeks and 26 weeks

  2. Change in plaque levels as measured by Modified Quigley and Hein Plaque Index

    Plaque was disclosed and assessed using modified Quigley and Hein plaque index (MQHPI) \[2\]. The scoring criteria were: 0 = No plaque; 1 = Separate flecks of plaque at the cervical margin of the tooth; 2 = A thin continuous band of plaque (up to one mm) at the cervical margin of the tooth; 3 = A band of plaque wider than one mm but covering less than 1/3 of the crown of the tooth; 4 = Plaque covering at least one-third but less than 2/3 of the crown of the tooth; 5 = Plaque covering 2/3 or more of the crown of the tooth. Each eligible tooth was scored at six sites: facial (body, mesial, distal) and lingual (body, mesial, distal). The participant's score at each timepoint is the average of all tooth sites measured.

    Time frame: 4 weeks, 13 weeks and 26 weeks

07

Study locations

1 site
  • Hospital of Stomatology, Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
08

References and documents

Publications

  • Turesky S, Gilmore ND, Glickman I. Reduced plaque formation by the chloromethyl analogue of victamine C. J Periodontol. 1970 Jan;41(1):41-3. doi: 10.1902/jop.1970.41.41.41. No abstract available. PubMed 5264376 ↗
  • LOE H, SILNESS J. PERIODONTAL DISEASE IN PREGNANCY. I. PREVALENCE AND SEVERITY. Acta Odontol Scand. 1963 Dec;21:533-51. doi: 10.3109/00016356309011240. No abstract available. PubMed 14121956 ↗
  • Hu X, Zhang P, Zhang L, Matheson JR, Lin S, Sun JN, Delfanti C, Tian J, Gupta AK, Vasantharaghavan R, Huang R. The effect of enzyme and protein containing toothpaste on gingival condition: a randomised controlled study. BMC Oral Health. 2025 Nov 3;25(1):1727. doi: 10.1186/s12903-025-07096-7. PubMed 41184910 ↗

Individual participant data

Plan to share: No — Consent was not obtained from participants for this purpose.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Apr 2019, 6 months.

Of 53 industry-sponsored interventional studies with no phase under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 5. This study's 6 months is above that.

Counting every sponsor, half of 257 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 17, 2025
StartActual
Oct 29, 2018
Primary completionActual
Apr 30, 2019
CompletionActual
Apr 30, 2019
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06932211
Lead sponsor
Unilever R&D
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
Oct 29, 2018
Primary completion
Apr 30, 2019
Completion
Apr 30, 2019
Last update
Sep 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion